Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman and D. Ross Camidge Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer Cancer 118
Article first published online: 4 APR 2012 | DOI: 10.1002/cncr.27450
Crizotinib therapy causes rapid suppression of testosterone levels in men. The site of action must include a central (hypothalamic or pituitary) effect, but additional direct testicular effects cannot be excluded.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field